Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.055 HKD
−231.34 M HKD
96.31 M HKD
1.68 B
About MABPHARM LTD
Sector
CEO
Hao Wang
Website
Headquarters
Hong Kong
Founded
2015
FIGI
BBG00P5G4RJ9
Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company was founded on June 1, 2018 and is headquartered in Hong Kong.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 2181 is 0.375 HKD — it hasn't changed in the past 24 hours. Watch MABPHARM LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange MABPHARM LTD stocks are traded under the ticker 2181.
2181 stock has fallen by −4.29% compared to the previous week, the month change is a 8.06% rise, over the last year MABPHARM LTD has showed a −24.24% decrease.
2181 reached its all-time high on May 18, 2020 with the price of 1.800 HKD, and its all-time low was 0.250 HKD and was reached on Jan 19, 2024. View more price dynamics on 2181 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
2181 stock is 12.00% volatile and has beta coefficient of 0.90. Track MABPHARM LTD stock price on the chart and check out the list of the most volatile stocks — is MABPHARM LTD there?
Today MABPHARM LTD has the market capitalization of 1.38 B, it has increased by 13.56% over the last week.
Yes, you can track MABPHARM LTD financials in yearly and quarterly reports right on TradingView.
MABPHARM LTD is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
2181 net income for the last half-year is −105.73 M HKD, while the previous report showed −118.14 M HKD of net income which accounts for 10.51% change. Track more MABPHARM LTD financial stats to get the full picture.
No, 2181 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 347.00 employees. See our rating of the largest employees — is MABPHARM LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MABPHARM LTD EBITDA is −144.60 M HKD, and current EBITDA margin is −161.61%. See more stats in MABPHARM LTD financial statements.
Like other stocks, 2181 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MABPHARM LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MABPHARM LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MABPHARM LTD stock shows the sell signal. See more of MABPHARM LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.